The French biotechnology company $Abivax S.A. (ABVX.US)$ had a market capitalization of less than USD 5 billion at the beginning of the year. Following a rapid surge, its market value now exceeds USD 8 billion, with some analysts believing there is still significant upside potential. Market optimism began in July when Abivax announced positive data for its experimental drug to treat chronic inflammatory bowel disease. This propelled the stock price to rise by over 1300%, making it the best-performing stock in the European benchmark STOXX 600 Index this year.
Bullish Reason One: High Potential of Intestinal Inflammation Drug
Investors are closely watching whether ulcerative colitis patients taking Abivax’s obefazimod tablets will maintain remission. The study results are expected to be released in the second quarter of 2026, and if successful, Abivax will be able to submit the drug for regulatory approval. Additionally, the company is expected to release interim trial results for the tablet's treatment of another inflammatory bowel disease, Crohn’s disease, in the second half of this year.
Abivax CEO Marc de Garidel stated, 'The more we research this drug, the more excited we become. Although we are a small company, we aim to lead the market with an exceptional drug.'
For Abivax, which is dual-listed in Paris and New York, the stakes are high. The company initially explored obefazimod as a potential HIV treatment. Morgan Stanley’s optimistic valuation suggests that its American Depositary Receipts (ADRs) could rise over 40% from current levels, while a pessimistic scenario could see them plummet by more than 90%. In a report published in September, Morgan Stanley analysts highlighted that the potential success or failure of obefazimod in treating ulcerative colitis and Crohn’s disease is seen as a key catalyst for the company’s share price.
Nevertheless, the drug’s therapeutic effects have shown positive momentum. Obefazimod is an orally administered small molecule drug with a mechanism of action distinct from existing inflammatory bowel disease (IBD) therapies. It modulates inflammatory responses by upregulating a microRNA called miR-124, rather than directly inhibiting inflammatory factors. This endogenous regulatory approach is believed to better balance efficacy and safety, particularly in highly inflammatory environments.
In clinical trials of obefazimod, adverse events were observed to be few and mild, primarily consisting of headaches, without serious side effects such as cardiovascular events or carcinogenicity. In contrast, some existing IBD therapies (e.g., JAK inhibitors) carry warnings of severe side effects. This differentiated safety advantage makes obefazimod a more attractive treatment option, especially for younger patient populations requiring long-term medication.
Ulcerative colitis and Crohn’s disease are inflammatory bowel diseases that can cause frequent diarrhea and stomach pain. Analysts at Wolfe Research believe that obefazimod has the potential to achieve peak sales of approximately EUR 6 billion (USD 7 billion), capturing a “significant” market share in the treatment of these two conditions. The success of obefazimod is expected to secure a substantial position in this market, which is projected to reach approximately USD 30 billion by 2030.
This experimental drug has already demonstrated encouraging results. In July this year, Abivax reported that in late-stage trials, patients taking obefazimod saw their symptoms of moderate to severe active ulcerative colitis disappear after eight weeks. Sebastiaan van der Schoot, an analyst at Van Lanschot Kempen, stated that based on previous interim trial data, these results were “outstanding and exceeded everyone’s expectations.”
According to van der Schoot, the so-called induction trial results indicate that Abivax’s tablet demonstrates efficacy “among the strongest across all options, including injectables.”
de Garidel stated that the company plans to submit the drug candidate for U.S. regulatory approval by the end of 2026, depending on the late-stage trial data scheduled for release in the second quarter. He added, "We have an aggressive timeline for filing, with the goal of launching in the U.S. in the third quarter of 2027."
Bullish Reason Two: Abivax Becomes a Hot Acquisition Target
Meanwhile, investors have been rushing to buy the stock, particularly because Abivax has been touted as a potential acquisition target. Last month, Truist Securities referred to the company as a 'strategically attractive potential acquisition darling.' Meanwhile, Goldman Sachs recently included Abivax on its list of stocks most favored by hedge funds.
However, potential acquirers still need to proceed cautiously. Swiss biopharmaceutical company MoonLake Immunotherapeutics saw its market value plummet after releasing late-stage trial data for one of its experimental dermatological treatments in late September. Analysts noted that the results failed to demonstrate superiority over competing drugs already available on the market. Previously considered an attractive acquisition target with a market value that once soared to $40 billion, MoonLake is now valued at only about $10 billion.
Jared Holz, a healthcare expert at Mizuho Securities, stated, 'Pharmaceutical companies tend to be more risk-averse in mergers and acquisitions and favor assets that have demonstrated late-stage clinical data. This means they are willing to pay a premium for such visibility.'
Nevertheless, Holz remains 'very optimistic' about the near-term prospects of the biotech sector, given the flurry of deal activity in recent months. The Nasdaq Biotechnology Index is hovering near record highs and has risen approximately 30% year-to-date. Continued positive clinical trial results will help sustain this momentum.
Antoine Papiernik, Chairman and Managing Partner of European venture capital firm Sofinnova Partners, said, 'Data matters, and our portfolio needs to prove through data that it deserves attention.' The company is an investor in Abivax.
Currently, Wall Street analysts have reached a consensus rating of 'Buy' or 'Strong Buy' for Abivax, with an overall optimistic outlook. The average price target is estimated to be around $120 to $130.
Editor/Doris
